Standard Risk B-precursor Acute Lymphoblastic Leukemia.

Trial Profile

Standard Risk B-precursor Acute Lymphoblastic Leukemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Folinic acid (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Doxorubicin; Mercaptopurine; Tioguanine; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2016 Results of risk stratification in childhood B-LL data from two studies including this study presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Jun 2013 Analysis assessing incidence of treatment-related osteonecrosis presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top